Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q4 FY23 results · Jan–Mar 2023
Marksans Pharma reported revenue from operations of ₹485.98 crore (up 16.3% from Q4 FY22) and net profit of ₹82.71 crore (up 178.9% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 485.98 | 418.04 | +16.3% | 479.83 | +1.3% |
| Other income | 11.01 | 15.34 | −28.3% | 17.65 | −37.6% |
| Total income | 496.99 | 433.39 | +14.7% | 497.48 | −0.1% |
| Profit before tax | 104.17 | 52.60 | +98.1% | 79.20 | +31.5% |
| Net profit for the period | 82.71 | 29.65 | +178.9% | 62.31 | +32.7% |
| EPS, basic (₹) | 1.97 | 0.69 | not comparable | 1.56 | not comparable |
| Net margin (%) | 17.0 | 7.1 | 13.0 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 153.04 | 176.28 | −13.2% | 172.75 | −11.4% |
| Other income | 4.30 | 7.65 | −43.7% | 15.71 | −72.6% |
| Total income | 157.35 | 183.93 | −14.5% | 188.46 | −16.5% |
| Profit before tax | 22.84 | 28.63 | −20.2% | 34.50 | −33.8% |
| Net profit for the period | 17.81 | 21.43 | −16.9% | 25.62 | −30.5% |
| EPS, basic (₹) | 0.43 | 0.52 | not comparable | 0.63 | not comparable |
| Net margin (%) | 11.6 | 12.2 | 14.8 |
Consolidated
- Filed with BSE
- 31 May 2023, 12:16 IST
- Board meeting
- 30 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 May 2023, 12:16 IST
- Board meeting
- 30 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE